Cheap Antidepressant Shows Promise Treating Early COVID

4
>>Follow Matzav On Whatsapp!<<

A cheap antidepressant reduced the need for hospitalization among high-risk adults with COVID-19 in a study hunting for existing drugs that could be repurposed to treat coronavirus.

Researchers tested the pill used for depression and obsessive-compulsive disorder because it was known to reduce inflammation and looked promising in smaller studies.

They’ve shared the results with the U.S. National Institutes of Health, which publishes treatment guidelines, and they hope for a World Health Organization recommendation.

“If WHO recommends this, you will see it widely taken up,” said study co-author Dr. Edward Mills of McMaster University in Hamilton, Ontario, adding that many poor nations have the drug readily available. “We hope it will lead to a lot of lives saved.”

The pill, called fluvoxamine, would cost $4 for a course of COVID-19 treatment. By comparison, antibody IV treatments cost about $2,000 and Merck’s experimental antiviral pill for COVID-19 is about $700 per course. Some experts predict various treatments eventually will be used in combination to fight the coronavirus.

Read more at NEWSMAX.

{Matzav.com}


4 COMMENTS

  1. everyone – watch this. Soon the government will take this off the market just as they did to hydroxychloroquine. Also, as soon as Israel came out with a study that a low-dose aspirin regimen gave protection from covid-related complications (probably the clots), the NY Times put out a statement from a “panel of experts” that people should stop taking low-dose aspirin as a prevention for heart attacks and strokes. I truly believe there is a conspiracy here between the government and the vaccine producers to shut everything else out. They are killing peopple, but we knew that already.

  2. Had it been known previously that these cheap antidepressants “reduced the need for hospitalization among high-risk adults with COVID-19,” perhaps there would be less depressed people, which would then cause less people to take antidepressants, which would then trigger an increase in hospitalization among high-risk adults with COVID-19.

  3. Zoloft is made by Pfizer so it wouldn’t get covered up.
    It should be easy to run statistics on this.
    I wonder if it’s true.

LEAVE A REPLY

Please enter your comment!
Please enter your name here